<i>IL1RL1</i>variant may affect the response to type 2 biologics in patients with severe asthma
<i>IL1RL1</i> rs1420101 TT genotype and/or <i>IL4RA</i> rs8832 GG genotype may predict an excellent or optimal response to biologic therapy in each patient, particularly to anti-interleukin-5 targeted therapy. The elucidation of genetic predisposition may improve the management of severe asthma in the era of biologics.
Authors
- Takahisa Kawaguchi (ORCID: https://orcid.org/0000-0001-7781-7404)
- Ryuta Haraguchi
- Satoru Terada (ORCID: https://orcid.org/0000-0003-1748-5502)
- Akiko Sano
- Hisako Matsumoto (ORCID: https://orcid.org/0000-0002-8754-6318)
- Kenta Nishi
- Chie Yoshimura
- Fumihiko Matsuda (ORCID: https://orcid.org/0000-0003-4557-4553)
- Toyohiro Hirai (ORCID: https://orcid.org/0000-0002-7431-9044)
- Yasuo Nishizaka
- Tsuyoshi Oguma (ORCID: https://orcid.org/0000-0001-5086-9407)
- Hironobu Sunadome (ORCID: https://orcid.org/0000-0002-4617-2348)
- Hiroyuki Sano (ORCID: https://orcid.org/0000-0002-8581-4809)
- Yuji Tohda
- Tadao Nagasaki (ORCID: https://orcid.org/0000-0002-3231-7841)
- Noriyuki Tashima
- Yusuke Hayashi (ORCID: https://orcid.org/0000-0003-2365-1220)
- Kyohei Morita
- Takashi Iwanaga
Institutions
- Kyoto University (JP)
- Kindai University Hospital (JP)
- Kyoto City Hospital (JP)
- Nara Medical University Hospital (JP)
- Osaka Red Cross Hospital (JP)
- Kitano Hospital (JP)
- Kindai University (JP)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1183/23120541.00448-2024
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.33
Funders
- Japanese Society of Allergology